Is a statin as part of a polypill the answer?
Statins are a necessary component of a polypill. Almost all patients have the potential to benefit from low-density lipoprotein cholesterol reduction with statins, although absolute benefits due to the reduction in coronary heart disease and stroke vary by risk level. The reduction in coronary heart disease and stroke from antihypertensive therapy is additive to the reduction in risk from statins. Used in combination with antihypertensive therapy, a moderate-dose statin would be expected to reduce cardiovascular risk by at least 50%, and a high-dose statin would be expected to reduce risk by at least 60% over an approximately 5-year period. A polypill containing aspirin in addition to a statin and antihypertensive therapy would be appropriate for most men over age 55 years, but not for high-risk women until age 65 years and moderately high-risk women until age 75 years. Polypills in development hold great promise for reducing the global burden of cardiovascular disease.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 7.Pfizer Inc.: Lipitor (atorvastatin calcium) [prescribing information]. Available at: http://www.pfizer.com/files/products/uspi_lipitor.pdf. Accessed on June 7, 2008.
- 8.Merck & Co.: Mevacor (lovastatin) [prescribing information]. Available at: http://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_pi.pdf. Accessed on July 1, 2008.
- 9.Merck & Co.: Zocor (simvastatin) [prescribing information]. Available at: http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf Accessed on June 7, 2008.
- 15.National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.Google Scholar
- 26.LaRosa JC, Grundy SM, Kastelein JJ, et al.; Treating to New Targets (TNT) Steering Committee and Investigators: Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol 2007, 100:747–752.PubMedCrossRefGoogle Scholar
- 27.AstraZeneca Pharmaceuticals: Crestor (rosuvstatin calcium) [prescribing information]. Available at http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed on February 10, 2007.
- 32.Law MR, Wald NJ, Morris J: Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assessment 2003, 7:1–108.Google Scholar
- 39.Nainggolan L: Clinical trials of polypills for CVD begin. Available at: http://www.medscape.com/viewarticle/551002. Accessed on June 13, 2008.
- 40.World Heart Federation: Polypill reaches clinical testing phase [press release]. Available at: http://www.worldheart.org/press/press-releases/news-details/article/polypillreaches-clinical-testing-phase-1/. Accessed on July 1, 2008.
- 41.Stiles S: Polypill progress: clinical testing imminent for three-agent secondary-prevention pill. Available at: http://www.theheart.org/article/868981.do. Accessed on July 1, 2008.
- 42.Templeton S: Over 55s to get life-saving polypill. Sunday-Times. May 4, 2008.Google Scholar
- 43.Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955–1964.PubMedCrossRefGoogle Scholar
- 44.Population Division, U.S. Census Bureau: Table 1: Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2007 (NC-EST2007-01); May 1, 2008.Google Scholar